Literature DB >> 10319193

Metabolism of tricyclic antidepressants.

M V Rudorfer1, W Z Potter.   

Abstract

1. Despite the considerable advances in the treatments available for mood disorders over the past generation, tricyclic antidepressants (TCAs) remain an important option for the pharmacotherapy of depression. 2. The pharmacokinetics of TCAs are characterized by substantial presystemic first-pass metabolism, a large volume of distribution, extensive protein binding, and an elimination half-life averaging about 1 day (up to 3 days for protriptyline). 3. Clearance of tricyclics is dependent primarily on hepatic cytochrome P450 (CYP) oxidative enzymes. Although the activities of some P450 isoenzymes are largely under genetic control, they may be influenced by external factors, such as the concomitant use of other medications or substances. Patient variables, such as ethnicity and age, also affect TCA metabolism. The impact of gender and related reproductive issues is coming under increased scrutiny. 4. Metabolism of TCAs, especially their hydroxylation, results in the formation of active metabolites, which contribute to both the therapeutic and the adverse effects of these compounds. 5. Renal clearance of the polar metabolites of TCAs is reduced by normal aging, accounting for much of the increased risk of toxicity in older patients. 6. Knowledge of factors affecting the metabolism of TCAs can further the development and understanding of newer antidepressant medications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10319193     DOI: 10.1023/a:1006949816036

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  185 in total

Review 1.  Cytochrome P-450 monooxygenases and interactions of psychotropic drugs.

Authors:  W W Shen; K M Lin
Journal:  Int J Psychiatry Med       Date:  1991       Impact factor: 1.210

2.  Fenfluramine and the cytochrome P450 system.

Authors:  D L Fogelson
Journal:  Am J Psychiatry       Date:  1997-03       Impact factor: 18.112

3.  Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients.

Authors:  T A Sutfin; G I Perini; G Molnar; W J Jusko
Journal:  J Clin Psychopharmacol       Date:  1988-02       Impact factor: 3.153

4.  The nonlinear kinetics of desipramine and 2-hydroxydesipramine in plasma.

Authors:  R G Cooke; J J Warsh; H C Stancer; K L Reed; E Persad
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

5.  Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.

Authors:  S H Preskorn; J Alderman; M Chung; W Harrison; M Messig; S Harris
Journal:  J Clin Psychopharmacol       Date:  1994-04       Impact factor: 3.153

6.  Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder.

Authors:  B Geller; T B Cooper; D L Graham; H H Fetner; F A Marsteller; J M Wells
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1992-01       Impact factor: 8.829

7.  Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.

Authors:  B G Pollock; J M Perel; L P Altieri; M Kirshner; A L Fasiczka; P R Houck; C F Reynolds
Journal:  Psychopharmacol Bull       Date:  1992

8.  Pharmacokinetics of amoxapine and its active metabolites.

Authors:  B Calvo; M J García; J L Pedraz; E L Mariño; A Domínguez-Gil
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-04

Review 9.  Challenges in medication clinical trials.

Authors:  M V Rudorfer
Journal:  Psychopharmacol Bull       Date:  1993

Review 10.  Comparative tolerability profiles of the newer versus older antidepressants.

Authors:  M V Rudorfer; H K Manji; W Z Potter
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

View more
  21 in total

1.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

Review 2.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

Review 3.  Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

Authors:  J K Hicks; J J Swen; C F Thorn; K Sangkuhl; E D Kharasch; V L Ellingrod; T C Skaar; D J Müller; A Gaedigk; J C Stingl
Journal:  Clin Pharmacol Ther       Date:  2013-01-16       Impact factor: 6.875

4.  A Simple, Rapid and Reliable Method to Determine Imipramine and Desipramine in Mouse Serum Using Ultra-High-Performance Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry.

Authors:  Jing Zhao; Yujin Shin; Kwang-Hoon Chun; Hye-Ran Yoon; Jeongmi Lee
Journal:  J Chromatogr Sci       Date:  2015-12-19       Impact factor: 1.618

5.  Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.

Authors:  J K Hicks; K Sangkuhl; J J Swen; V L Ellingrod; D J Müller; K Shimoda; J R Bishop; E D Kharasch; T C Skaar; A Gaedigk; H M Dunnenberger; T E Klein; K E Caudle; J C Stingl
Journal:  Clin Pharmacol Ther       Date:  2017-02-13       Impact factor: 6.875

Review 6.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

Review 7.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants.

Authors:  Thomas M Polasek; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

Review 9.  Pharmacokinetics of antidepressants in patients with hepatic impairment.

Authors:  Massimo Carlo Mauri; Alessio Fiorentini; Silvia Paletta; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

10.  In vivo and in vitro evidence of the sex-dependent pharmacokinetics and disposition of G004, a potential hypoglycemic agent, in rats.

Authors:  Linlin Hu; Janvier Engelbert Agbokponto; Xiaobing Li; Li Ding; Bing Liu; Shuisheng Zhong; Xiaoyu Zhang; Yiwei Du
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-04-03       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.